瘦型脂肪性肝病的临床特点及研究进展

摘要/Abstract

摘要： 10%~20%的代谢相关脂肪性肝病患者体质指数相对正常,这种情况通常被描述为瘦型脂肪性肝病(瘦型SLD)。基于肝组织学和非侵入性纤维化试验的研究表明,瘦型SLD患者也可能像我们在肥胖患者中看到的那样发展至代谢相关脂肪性肝炎和晚期纤维化。越来越多的证据表明,瘦型SLD拥有独特的病理生理学发展及更差的预后,而缺乏相应的诊断策略及有效治疗方案,因此,本文就瘦型 SLD相关病理生理机制、临床特点及目前研究进展进行综述。

王辉, 边娜娜, 孙荣荣, 张心怡, 王梓依, 郝帅, 张粉娜, 贺娜. 瘦型脂肪性肝病的临床特点及研究进展[J]. 肝脏, 2024, 29(10): 1172-1175.

/ 推荐

参考文献

[1] Brunt Em, Wong Vw, Nobili V, et al. Nonalcoholic fatty liver disease [J]. Nat Rev Dis Primers, 2015, 1: 15080.
[2] Wong Vw, Wong Gl, Chan Rs, et al. Beneficial effects of lifestyle intervention in non-obese patients with [J]. J Hepatol, 2018, 69(6): 1349-1356.
[3] Wei Jl, Leung Jc, Loong Tc, et al. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese [J]. Am J Gastroenterol, 2015, 110(9): 1306-1314.
[4] Kim D, Kim Wr. Nonobese Fatty Liver Disease [J]. Clin Gastroenterol Hepatol, 2017, 15(4): 474-485.
[5] Golabi P, Paik J, Fukui N, et al. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal [J]. Clin Diabetes, 2019, 37(1): 65-72.
[6] Lu Fb, Zheng Ki, Orcid Id, et al. Global epidemiology of Lean non-alcoholic fatty liver disease: A systematic [J]. J Gastroenterol Hepatol, 2020, 35(12): 2041-2050.
[7] Wang Q, You H, Ou X, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry [J]. Hepatol Int, 2019, 13(6): 766-776.
[8] Maier S, Orcid Id, Wieland A, et al. Lean NAFLD: an underrecognized and challenging disorder in medicine [J]. Rev Endocr Metab Disord, 2021, 22(2): 351-366.
[9] Young S, Tariq R, Provenza J, et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults [J]. Hepatol Commun, 2020, 4(7): 953-972.
[10] Younossi Zm, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in Lean individuals in the United States [J]. Medicine (Baltimore), 2012, 91(6): 319-327.
[11] Das K, Das K, Mukherjee Ps, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic [J]. Hepatology, 2010, 51(5): 1593-1602.
[12] Kwon Ym, Oh Sw, Hwang Ss, et al. Association of nonalcoholic fatty liver disease with components of metabolic [J]. Am J Gastroenterol, 2012, 107(12): 1852-1858.
[13] Sinn Dh, Gwak Gy, Park Hn, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent [J]. Am J Gastroenterol, 2012, 107(4): 561-567.
[14] Choudhary Ns, Saraf N, Saigal S, et al. Nonalcoholic Fatty Liver in Lean Individuals: Clinicobiochemical Correlates of [J]. J Clin Exp Hepatol, 2021, Sep-Oct; 11(5): 544-549.
[15] Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross [J]. Hepatol Int, 2020, 14(2): 259-269.
[16] Amarapurkar Dn, Hashimoto E, Lesmana La, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and [J]. J Gastroenterol Hepatol, 2007, 22(6): 788-793.
[17] Wang Ay, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease [J]. Clin Nutr, 2019, 38(3): 975-981.
[18] Vilarinho S, Ajmera V, Orcid Id, et al. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With [J]. Hepatology, 2021, 74(4): 2241-2250.
[19] Meroni M, Orcid Id, Longo M, et al. Genetics Is of the Essence to Face NAFLD [J]. Biomedicines, 2021, 9(10): 1359.
[20] Pingitore P, Romeo S. The role of PNPLA3 in health and disease [J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(6): 900-906.
[21] Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic [J]. Hepatol , 2016, 46(10): 1011-1018.
[22] Fracanzani Al, Petta S, Lombardi R, et al. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver [J]. Clin Gastroenterol Hepatol, 2017, 15(10): 1604-1611.
[23] Treiber G, Flaus Furmaniuk A, Orcid Id, et al. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA [J]. Eur J Endocrinol, 2021, 185(4): 453-462.
[24] Hsu Cl, Wu Fz, Lin Kh, et al. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic [J]. Clin Transl Gastroenterol, 2019, 10(5): 1-8.
[25] Zhang X, Liu S, Dong Q, et al. The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant [J]. J Clin Transl Hepatol, 2018, 6(3): 326-331.
[26] Angulo P, Kleiner De, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term [J]. Gastroenterology, 2015, 149(2): 389-397.
[27] Patel Ya, Orcid Id, Gifford Ej, et al. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the [J]. Aliment Pharmacol Ther, 2018, 47(2): 268-278.
[28] Kim Hj, Kim Hj, Lee Ke, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese [J]. Arch Intern Med, 2004, 164(19): 2169-2175.
[29] Bugianesi E, Moscatiello S, Ciaravella Mf, et al. Insulin resistance in nonalcoholic fatty liver disease [J]. Curr Pharm Des, 2010, 16(17): 1941-1951.
[30] Leung Jc, Loong Tc, Wei Jl, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease [J]. Hepatology, 2017, 65(1): 54-64.
[31] Akyuz U, Yesil A, Yilmaz Y. Characterization of Lean patients with nonalcoholic fatty liver disease [J]. Scand J Gastroenterol, 2015, 50(3): 341-346.
[32] Bernhardt P, Kratzer W, Schmidberger J, et al. Laboratory parameters in Lean NAFLD: comparison of subjects with Lean NAFLD withobese subjects without hepatic steatosis [J]. BMC Res Notes, 2018, 11(1): 101.
[33] Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in Lean patients with nonalcoholic [J]. Hepatol Commun, 2017, 2(1): 48-57.
[34] Denkmayr L, Feldman A, Stechemesser L, et al. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological [J]. J Clin Med, 2018, 7(12): 562.
[35] Nobili V, Cutrera R, Liccardo D, et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell [J]. Am J Respir Crit Care Med, 2014, 189(1): 66-76.
[36] Alam S, Gupta Ud, Alam M, et al. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh[J]. Indian J Gastroenterol, 2014, 33(5): 452-457.
[37] Fu C, Wai Jw, Nik Mustapha Nr, et al. Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic [J]. Clin Gastroenterol Hepatol, 2020, (12): 2843-2845.
[38] Wong Vw, Tak Wy, Goh Gbb, et al. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and [J]. Clin Gastroenterol Hepatol, 2023, 21(1): 90-102.
[39] Hagström H, Talbäck M, Andreasson A, et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver [J]. J Hepatol, 2020, 73(5): 1023-1029.
[40] Zhang X, Wong Gl, Wong Vw. Application of transient elastography in nonalcoholic fatty liver disease [J]. Clin Mol Hepatol, 2020, 26(2): 128-141.
[41] Wong Vw, Irles M, Wong Gl, et al. Unified interpretation of liver stiffness measurement by M and XL probes in [J]. Gut, 2019, 68(11): 2057-2064.
[42] Wong Vw, Chan Rs, Wong Gl, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver [J]. J Hepatol, 2013, 59(3): 536-542.
[43] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of [J]. Gastroenterology, 2015, 149(2): 367-e15.